Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Correction to: Post-induction MRD by FCM and GATA1-PCR are significant prognostic factors for myeloid leukemia of Down syndrome

The Original Article was published on 15 February 2021

Correction to: Leukemia, published online 15 February 2021

Following the publication of this article, the authors noted an error in the data reported.

One patient in the AML-D11 study (showing negativity for both FCM-MRD and GATA1-MRD) was incorrectly reported dead after relapse following a data input error. After re-confirming the survival data for all other patients, the dataset has been updated and results are as follows.

  • The number of patients who relapsed was decreased from 7 to 6.

  • The 3-year event-free survival (EFS) and overall survival (OS) rates in the entire population (n = 78) were 88.5 and 91.0%.

  • The 3-year EFS and OS rates in the SR patients (n = 76) were 90.8 and 93.4%.

  • The 3-year EFS and OS rates were 95.0 and 96.7% in the FCM-MRD-negative population, and 60.0 and 80.0% in the positive population.

  • Three-year EFS and OS rates were both 98.1% in the GATA1-MRD-negative population, and 57.1 and 71.4% in the positive population.

  • The adjusted hazard ratios for the association of FCM-MRD with EFS and OS were 14.67 (95% CI, 2.00–107.79; p = 0.01) and 13.48 (0.81–224.27; p = 0.07), respectively, while multivariate analysis of GATA1-MRD did not converge in the updated dataset due to the limited number of events in the GATA1-MRD-negative population.

Table 2, Supplementary Table 4, and Figs. 3 and 4 have been corrected and are shown below.

The conclusions of the article remain unchanged.

Table 2 Multivariate Cox regression of FCM-MRD for event-free and overall survivals in the standard risk population.

Author information



Corresponding author

Correspondence to Takashi Taga.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Taga, T., Tanaka, S., Hasegawa, D. et al. Correction to: Post-induction MRD by FCM and GATA1-PCR are significant prognostic factors for myeloid leukemia of Down syndrome. Leukemia (2021).

Download citation


Quick links